EZZ Life Science Holdings Ltd
EZZ
Company Profile
Business description
EZZ Life Science Holdings Ltd is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papillomavirus (HPV), helicobacter pylori, and weight management. The company is engaged in formulation, production, marketing and sale of the EZZ branded health and wellbeing products to retailers and consumers domestically and internationally, and wholesale distribution of the EAORON branded skin care products to retailers in Australia and New Zealand.
Contact
55-59 Parramatta Road
Shop 1
LidcombeNSW2141
AUST: +61 291602305
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
What AI means for US software companies’ moats
We’re no longer certain that software firms will outperform over the next decade, but positive outcomes remain possible for names like Salesforce.
stocks
Lower moat ratings on four ASX shares due to AI
We believe AI weakens the competitive advantage of these companies.
stocks
What Q4 US earnings did and didn’t tell us about AI and the outlook for tech shares
Tech saw solid earnings, but there are more questions around which companies will benefit from AI, and which will be hurt.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,733.70 | 106.80 | -1.21% |
| CAC 40 | 7,993.49 | 52.31 | -0.65% |
| DAX 40 | 23,591.03 | 224.72 | -0.94% |
| Dow JONES (US) | 47,501.55 | 453.19 | -0.95% |
| FTSE 100 | 10,284.75 | 129.19 | -1.24% |
| HKSE | 25,135.35 | 621.94 | -2.41% |
| NASDAQ | 22,387.68 | 361.31 | -1.59% |
| Nikkei 225 | 51,740.46 | 3,880.38 | -6.98% |
| NZX 50 Index | 13,087.37 | 530.52 | -3.90% |
| S&P 500 | 6,740.02 | 90.69 | -1.33% |
| S&P/ASX 200 | 8,509.80 | 92.50 | -1.08% |
| SSE Composite Index | 4,081.89 | 42.30 | -1.03% |